Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
MLSS vs NVST vs XRAY vs ALGN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
Medical - Instruments & Supplies
Medical - Devices
MLSS vs NVST vs XRAY vs ALGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Equipment & Services | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $37M | $4.04B | $2.20B | $12.06B |
| Revenue (TTM) | $9M | $2.81B | $3.68B | $4.10B |
| Net Income (TTM) | $-7M | $68M | $-628M | $430M |
| Gross Margin | 72.8% | 55.1% | 48.9% | 67.7% |
| Operating Margin | -77.0% | 9.0% | 4.1% | 14.4% |
| Forward P/E | — | 17.0x | 7.7x | 14.8x |
| Total Debt | $349K | $1.71B | $2.47B | $114M |
| Cash & Equiv. | $3M | $1.21B | $326M | $1.08B |
MLSS vs NVST vs XRAY vs ALGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Milestone Scientifi… (MLSS) | 100 | 24.8 | -75.2% |
| Envista Holdings Co… (NVST) | 100 | 114.7 | +14.7% |
| DENTSPLY SIRONA Inc. (XRAY) | 100 | 23.6 | -76.4% |
| Align Technology, I… (ALGN) | 100 | 68.7 | -31.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MLSS vs NVST vs XRAY vs ALGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MLSS is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.94
- Lower volatility, beta 0.94, Low D/E 6.0%, current ratio 2.48x
- Beta 0.94, current ratio 2.48x
- Beta 0.94 vs XRAY's 1.78, lower leverage
NVST has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 8.3%, EPS growth 104.3%, 3Y rev CAGR 1.9%
- 8.3% revenue growth vs MLSS's -12.2%
- +44.2% vs MLSS's -48.5%
XRAY is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (7.7x vs 14.8x)
- 5.9% yield; 23-year raise streak; the other 3 pay no meaningful dividend
ALGN is the clearest fit if your priority is long-term compounding.
- 122.8% 10Y total return vs NVST's -13.1%
- 10.5% margin vs MLSS's -76.8%
- 6.9% ROA vs MLSS's -86.6%, ROIC 15.4% vs -121.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.3% revenue growth vs MLSS's -12.2% | |
| Value | Lower P/E (7.7x vs 14.8x) | |
| Quality / Margins | 10.5% margin vs MLSS's -76.8% | |
| Stability / Safety | Beta 0.94 vs XRAY's 1.78, lower leverage | |
| Dividends | 5.9% yield; 23-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +44.2% vs MLSS's -48.5% | |
| Efficiency (ROA) | 6.9% ROA vs MLSS's -86.6%, ROIC 15.4% vs -121.3% |
MLSS vs NVST vs XRAY vs ALGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MLSS vs NVST vs XRAY vs ALGN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALGN leads in 2 of 6 categories
XRAY leads 1 • NVST leads 1 • MLSS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALGN leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALGN is the larger business by revenue, generating $4.1B annually — 450.9x MLSS's $9M. ALGN is the more profitable business, keeping 10.5% of every revenue dollar as net income compared to MLSS's -76.8%. On growth, MLSS holds the edge at +25.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $9M | $2.8B | $3.7B | $4.1B |
| EBITDAEarnings before interest/tax | -$7M | $342M | $424M | $790M |
| Net IncomeAfter-tax profit | -$7M | $68M | -$628M | $430M |
| Free Cash FlowCash after capex | -$5M | $220M | $104M | $717M |
| Gross MarginGross profit ÷ Revenue | +72.8% | +55.1% | +48.9% | +67.7% |
| Operating MarginEBIT ÷ Revenue | -77.0% | +9.0% | +4.1% | +14.4% |
| Net MarginNet income ÷ Revenue | -76.8% | +2.4% | -17.1% | +10.5% |
| FCF MarginFCF ÷ Revenue | -57.9% | +7.8% | +2.8% | +17.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.3% | +14.4% | +0.1% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +130.0% | -150.0% | +23.6% |
Valuation Metrics
XRAY leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 29.8x trailing earnings, ALGN trades at a 66% valuation discount to NVST's 86.7x P/E. On an enterprise value basis, XRAY's 7.2x EV/EBITDA is more attractive than ALGN's 13.9x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $37M | $4.0B | $2.2B | $12.1B |
| Enterprise ValueMkt cap + debt − cash | $34M | $4.5B | $4.3B | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | -7.94x | 86.73x | -3.65x | 29.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.97x | 7.75x | 14.84x |
| PEG RatioP/E ÷ EPS growth rate | — | 58.08x | — | — |
| EV / EBITDAEnterprise value multiple | — | 13.28x | 7.18x | 13.92x |
| Price / SalesMarket cap ÷ Revenue | 4.27x | 1.49x | 0.60x | 2.99x |
| Price / BookPrice ÷ Book value/share | 6.42x | 1.32x | 1.63x | 3.02x |
| Price / FCFMarket cap ÷ FCF | — | 17.54x | 21.11x | 24.57x |
Profitability & Efficiency
ALGN leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALGN delivers a 10.7% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-2 for MLSS. ALGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to XRAY's 1.84x. On the Piotroski fundamental quality scale (0–9), NVST scores 7/9 vs MLSS's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.1% | +2.2% | -41.2% | +10.7% |
| ROA (TTM)Return on assets | -86.6% | +1.2% | -11.2% | +6.9% |
| ROICReturn on invested capital | -121.3% | +4.8% | +5.1% | +15.4% |
| ROCEReturn on capital employed | -94.2% | +4.9% | +6.1% | +14.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.06x | 0.55x | 1.84x | 0.03x |
| Net DebtTotal debt minus cash | -$3M | $496M | $2.1B | -$965M |
| Cash & Equiv.Liquid assets | $3M | $1.2B | $326M | $1.1B |
| Total DebtShort + long-term debt | $349,054 | $1.7B | $2.5B | $114M |
| Interest CoverageEBIT ÷ Interest expense | — | 12.76x | -5.12x | 389.13x |
Total Returns (Dividends Reinvested)
NVST leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NVST five years ago would be worth $5,340 today (with dividends reinvested), compared to $1,914 for MLSS. Over the past 12 months, NVST leads with a +44.2% total return vs MLSS's -48.5%. The 3-year compound annual growth rate (CAGR) favors NVST at -11.3% vs XRAY's -32.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +61.7% | +12.0% | -2.8% | +7.9% |
| 1-Year ReturnPast 12 months | -48.5% | +44.2% | -16.4% | -2.2% |
| 3-Year ReturnCumulative with dividends | -37.5% | -30.3% | -69.4% | -45.0% |
| 5-Year ReturnCumulative with dividends | -80.9% | -46.6% | -80.1% | -71.9% |
| 10-Year ReturnCumulative with dividends | -79.9% | -13.1% | -74.5% | +122.8% |
| CAGR (3Y)Annualised 3-year return | -14.5% | -11.3% | -32.6% | -18.1% |
Risk & Volatility
Evenly matched — MLSS and ALGN each lead in 1 of 2 comparable metrics.
Risk & Volatility
MLSS is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than XRAY's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALGN currently trades 80.8% from its 52-week high vs MLSS's 44.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.85x | 1.63x | 1.70x | 1.65x |
| 52-Week HighHighest price in past year | $1.05 | $30.42 | $17.18 | $208.31 |
| 52-Week LowLowest price in past year | $0.22 | $16.33 | $9.85 | $122.00 |
| % of 52W HighCurrent price vs 52-week peak | +44.7% | +79.8% | +63.8% | +80.8% |
| RSI (14)Momentum oscillator 0–100 | 72.6 | 55.1 | 39.2 | 44.6 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 2.4M | 4.2M | 1.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NVST as "Hold", XRAY as "Hold", ALGN as "Buy". Consensus price targets imply 25.5% upside for XRAY (target: $14) vs 13.0% for NVST (target: $27). XRAY is the only dividend payer here at 5.86% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | — | $27.44 | $13.75 | $203.60 |
| # AnalystsCovering analysts | — | 19 | 31 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | +5.9% | — |
| Dividend StreakConsecutive years of raises | — | — | 23 | — |
| Dividend / ShareAnnual DPS | — | — | $0.64 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.1% | 0.0% | +3.9% |
ALGN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XRAY leads in 1 (Valuation Metrics). 1 tied.
MLSS vs NVST vs XRAY vs ALGN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MLSS or NVST or XRAY or ALGN a better buy right now?
For growth investors, Envista Holdings Corp (NVST) is the stronger pick with 8.
3% revenue growth year-over-year, versus -12. 2% for Milestone Scientific Inc. (MLSS). Align Technology, Inc. (ALGN) offers the better valuation at 29. 8x trailing P/E (14. 8x forward), making it the more compelling value choice. Analysts rate Align Technology, Inc. (ALGN) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MLSS or NVST or XRAY or ALGN?
On trailing P/E, Align Technology, Inc.
(ALGN) is the cheapest at 29. 8x versus Envista Holdings Corp at 86. 7x. On forward P/E, DENTSPLY SIRONA Inc. is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — MLSS or NVST or XRAY or ALGN?
Over the past 5 years, Envista Holdings Corp (NVST) delivered a total return of -46.
6%, compared to -80. 9% for Milestone Scientific Inc. (MLSS). Over 10 years, the gap is even starker: ALGN returned +123. 3% versus MLSS's -80. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MLSS or NVST or XRAY or ALGN?
By beta (market sensitivity over 5 years), Milestone Scientific Inc.
(MLSS) is the lower-risk stock at 0. 85β versus DENTSPLY SIRONA Inc. 's 1. 70β — meaning XRAY is approximately 101% more volatile than MLSS relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MLSS or NVST or XRAY or ALGN?
By revenue growth (latest reported year), Envista Holdings Corp (NVST) is pulling ahead at 8.
3% versus -12. 2% for Milestone Scientific Inc. (MLSS). On earnings-per-share growth, the picture is similar: Envista Holdings Corp grew EPS 104. 3% year-over-year, compared to 0. 5% for Align Technology, Inc.. Over a 3-year CAGR, ALGN leads at 2. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MLSS or NVST or XRAY or ALGN?
Align Technology, Inc.
(ALGN) is the more profitable company, earning 10. 2% net margin versus -54. 6% for Milestone Scientific Inc. — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALGN leads at 15. 3% versus -78. 3% for MLSS. At the gross margin level — before operating expenses — MLSS leads at 74. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MLSS or NVST or XRAY or ALGN more undervalued right now?
On forward earnings alone, DENTSPLY SIRONA Inc.
(XRAY) trades at 7. 7x forward P/E versus 17. 0x for Envista Holdings Corp — 9. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XRAY: 25. 5% to $13. 75.
08Which pays a better dividend — MLSS or NVST or XRAY or ALGN?
In this comparison, XRAY (5.
9% yield) pays a dividend. MLSS, NVST, ALGN do not pay a meaningful dividend and should not be held primarily for income.
09Is MLSS or NVST or XRAY or ALGN better for a retirement portfolio?
For long-horizon retirement investors, Milestone Scientific Inc.
(MLSS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 85)). Envista Holdings Corp (NVST) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MLSS: -80. 4%, NVST: -13. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MLSS and NVST and XRAY and ALGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MLSS is a small-cap quality compounder stock; NVST is a small-cap quality compounder stock; XRAY is a small-cap income-oriented stock; ALGN is a mid-cap quality compounder stock. XRAY pays a dividend while MLSS, NVST, ALGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.